Welcome to our dedicated page for Prelude Therapeutics SEC filings (Ticker: PRLD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Prelude Therapeutics Incorporated filings document the formal disclosures of a clinical-stage precision oncology company developing targeted cancer therapies. Recent 8-K reports cover Regulation FD materials, financial results, FDA and IND-related updates for PRT12396, preclinical data for PRT13722, and investor presentation materials.
The company’s SEC record also includes proxy disclosures on board matters, shareholder voting, executive compensation, and equity awards. Capital-structure filings describe Prelude’s Nasdaq-listed common stock, shelf registration and prospectus supplement activity, and at-the-market equity sales arrangements, while other material-event reports document leadership appointments and related employment and compensation arrangements.